{{Rsnum
|rsid=4149117
|Gene=SLCO1B3
|Chromosome=12
|position=20858546
|Orientation=plus
|GMAF=0.2911
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=SLCO1B3
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 72.3 | 26.8 | 0.9
| HCB | 53.3 | 40.1 | 6.6
| JPT | 50.9 | 38.4 | 10.7
| YRI | 12.3 | 46.6 | 41.1
| ASW | 21.1 | 54.4 | 24.6
| CHB | 53.3 | 40.1 | 6.6
| CHD | 53.7 | 39.8 | 6.5
| GIH | 88.1 | 11.9 | 0.0
| LWK | 9.1 | 42.7 | 48.2
| MEX | 74.1 | 25.9 | 0.0
| MKK | 23.2 | 43.9 | 32.9
| TSI | 77.2 | 22.8 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4149117
|Name_s=SCLO1B3: exon 4 c.334T>G, mRNA 460T>G, p.Ser112Ala
|Gene_s=SLCO1B3
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19890249
|Annotation=Risk or phenotype-associated allele: SLCO1B3: T334. Phenotype: The metabolic ratio of glucuronidated mycophenolic acid (MPAG) to mycophenolic acid (MPA) showed a very significant decrease in carriers of the SLCO1B3 T334 allele (p = 0.0001). Carriers of at least one SLCO1B3 T334 allele (n = 22) had a 1.42-fold higher (p = 0.0003) MPA AUC(0-12 hours) and a 1.38-fold higher (p = 0.0010) Cmax as compared with carriers of the 334GG genotype (n = 48). Patients carrying 334 TT or TC genotypes (n = 22) had significantly higher MPA AUC(4-9 hours) than patients carrying the CC genotype (n = 48; p = 0.0027). However, they also had higher AUC(0-4 h) (p = 0.0008), resulting in an unchanged AUC(4-9 h)/AUC(0-9 h) ratio (p = 0.4945). In the subgroups of patients cotreated with sirolimus (n = 42) and tacrolimus (n = 28), the SLCO1B3: T334 allele was associated with a similar increase in MPA AUC(0-12 h) (p = 0.0074 and p = 0.0651, respectively) and decrease in MPAG/MPA metabolic ratio (p = 0.0517 and 0.0002, respectively); One-third of the patients with the 334 TT or TG genotype (n = 7/22) had MPA AUC(0-12 h) higher than the accepted therapeutic range, as compared with only 8% of patients with the 334GG genotype (n = 4/48). Conversely, among carriers of the 334GG genotype, 40% (n = 19/48) had MPA AUC(0-12 h) below the therapeutic range as compared with 23% (n = 5/22) of patients with the TT or TG genotype. Study size: 70. Study population/ethnicity: Caucasian cohort from the SOPHIE study cotreated with MMF and either sirolimus or tacrolimus. Significance metric(s): p <= 0.05. Type of association: GN; PK
|Drugs=mycophenolate mofetil; mycophenolic acid; sirolimus; tacrolimus
|Drug Classes=
|Diseases=Organ Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165109804
}}

{{PharmGKB
|RSID=rs4149117
|Name_s=SCLO1B3: exon 4 c.334T>G, mRNA 460T>G, p.Ser112Ala
|Gene_s=SLCO1B3
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19890249
|Annotation=Risk or phenotype-associated allele: SCLO1B3 haplotype formed by 112Ser>Ala (rs4149117, 334T>G) and 223Met>Ile (rs7311358, 699G>A). Phenotype: HEK293 cells transiently expressing the SCLO1B3 334G-699A haplotype or reference haplotype were incubated in the presence of increasing concentrations of mycophenolic acid phenyl-glucuronide (MPAG) for 10 min. The uptake of MPAG according to the SCLO1B3 334G-699A haplotype was markedly lower than in cells expressing the reference sequence 334T-669G. Type of association: GN; FA; PK
|Drugs=mycophenolic acid
|Drug Classes=
|Diseases=Organ Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165109800
}}

{{PMID Auto
|PMID=21266523
|Title=Expression of SLCO transport genes in castration resistant prostate cancer and impact of genetic variation in SCLO1B3 and SLCO2B1 on prostate cancer outcomes
|OA=1
}}

{{PMID Auto
|PMID=22136368
|Title=Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
}}

{{GET Evidence
|gene=SLCO1B3
|aa_change=Ser112Ala
|aa_change_short=S112A
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4149117
|overall_frequency_n=7725
|overall_frequency_d=10756
|overall_frequency=0.718204
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=72
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=-1
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}